Viewing data from:

CABERGOLINE

ANDA

CABERGOLINE | A076310 | STRIDES PHARMA INTERNATIONAL AG

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Cabergoline (2023)

Total Spending

$8.6M

Total Claims

81,164

Beneficiaries

19,362

Avg Cost/Unit

$7.10

Spending Trend

$7.9M(2019)→$8.0M(2020)→$9.2M(2021)→$9.8M(2022)→$8.6M(2023)

YoY Change:-16.9%

5yr CAGR:-10.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs9 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

FINETECH PHARMACEUTICAL LTDCABERGOLINE DRUG SUBSTANCE

DMF 154232001

TAPI NL BVCABERGOLINE

DMF 181132005

CF PHARMA LTDCABERGOLINE

DMF 321452017

ANTIBIOTICOS SPAInactiveCABERGOLINE ACTIVE DRUG SUBSTANCE

DMF 75331988

ANTIBIOTICOS SPAInactiveCABERGOLINE FINISHED DOSAGE

DMF 75341988

IVAX CRInactiveCABERGOLINE

DMF 159332002

GEDEON RICHTER PLCInactiveCABERGOLINE

DMF 181992005

RESOLUTION CHEMICALS LTDInactiveCABERGOLINE DRUG SUBSTANCE

DMF 189722005

APOTEX PHARMACHEM INDIA PVT LTDInactiveCABERGOLINE USP

DMF 226202009

MYLAN LABORATORIES LTDInactiveCABERGOLINE USP

DMF 239182010

APOTEX PHARMACHEM INDIA PVT LTDInactiveCABERGOLINE USP

DMF 262352012

PFIZER INCInactiveCABERGOLINE USP

DMF 287422014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 6, 2006	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.5MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Dec 29, 2005

No patent or exclusivity listings for this strength.